Literature DB >> 16378892

Pulmonary mucormycosis: two of a kind.

Ritesh Agarwal1, Vijay Kumar, D Gupta.   

Abstract

Mucormycosis is an uncommon infection caused by fungi of the class Zygomycetes, suborder Mucorales. It occurs predominantly in the immunodeficient host, the most common risk factor being diabetes mellitus. Pulmonary mucormycosis is a disease that is localized in the lungs or mediastinum. It usually presents in a fulminant manner, although a chronic presentation can also occur. We describe two cases of pulmonary mucormycosis in patients with diabetes mellitus, one with an acute and the other with a chronic presentation. A high level of clinical suspicion, combined surgical and medical therapy, and control of patient's underlying immunosuppression are the key to a successful outcome.

Entities:  

Year:  2006        PMID: 16378892     DOI: 10.1016/j.ejim.2005.08.009

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  8 in total

1.  Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus.

Authors:  Nousheen Iqbal; Muhammad Irfan; Kauser Jabeen; Murtaza Mohammed Kazmi; Muhammad Usman Tariq
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

2.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

3.  Clinical features of pulmonary mucormycosis in patients with different immune status.

Authors:  Min Peng; Hua Meng; Yinghao Sun; Yu Xiao; Hong Zhang; Ke Lv; Baiqiang Cai
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  Isolated cerebellar mucormycosis, slowly progressive over 1 year in an immunocompetent patient.

Authors:  Ellen L Air; Achala A Vagal; Ady Kendler; Christopher M McPherson
Journal:  Surg Neurol Int       Date:  2010-12-13

5.  Pulmonary Artery Pseudoaneurysm in COVID-19-Associated Pulmonary Mucormycosis: Case Series and Systematic Review of the Literature.

Authors:  Himanshu Pruthi; Valliappan Muthu; Harish Bhujade; Arun Sharma; Abhiman Baloji; Rao G Ratnakara; Amanjit Bal; Harkant Singh; Manavjit Singh Sandhu; Sunder Negi; Arunaloke Chakrabarti; Manphool Singhal
Journal:  Mycopathologia       Date:  2021-12-22       Impact factor: 2.574

6.  IFN-γ Mediated Signaling Improves Fungal Clearance in Experimental Pulmonary Mucormycosis.

Authors:  Amanda Ribeiro Dos Santos; Thais Fernanda Fraga-Silva; Débora de Fátima Almeida-Donanzam; Rodolfo Ferreira Dos Santos; Angela Carolina Finato; Cleverson Teixeira Soares; Vanessa Soares Lara; Nara Lígia Martins Almeida; Maria Izilda Andrade; Olavo Speranza de Arruda; Maria Sueli Parreira de Arruda; James Venturini
Journal:  Mycopathologia       Date:  2021-10-29       Impact factor: 2.574

Review 7.  Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.

Authors:  Valliappan Muthu; Ritesh Agarwal; Atul Patel; Soundappan Kathirvel; Ooriapadickal Cherian Abraham; Ashutosh Nath Aggarwal; Amanjit Bal; Ashu Seith Bhalla; Prashant N Chhajed; Dhruva Chaudhry; Mandeep Garg; Randeep Guleria; Ram Gopal Krishnan; Arvind Kumar; Uma Maheshwari; Ravindra Mehta; Anant Mohan; Alok Nath; Dharmesh Patel; Shivaprakash Mandya Rudramurthy; Puneet Saxena; Nandini Sethuraman; Tanu Singhal; Rajeev Soman; Balamugesh Thangakunam; George M Varghese; Arunaloke Chakrabarti
Journal:  Lancet Infect Dis       Date:  2022-04-04       Impact factor: 71.421

8.  Pulmonary mucormycosis: A case report and review of the literature.

Authors:  Xi-Ming Wang; Ling-Chuan Guo; Sheng-Li Xue; Yan-Bin Chen
Journal:  Oncol Lett       Date:  2016-03-22       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.